Kolesterolsænkende behandling med PCSK9-inhibitorer

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Kolesterolsænkende behandling med PCSK9-inhibitorer. / Røder, Michael E; Hildebrandt, Per; Storgaard, Heidi; Heitmann, Merete.

I: Ugeskrift for Laeger, Bind 180, Nr. 20A, V11170831, 2018.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Røder, ME, Hildebrandt, P, Storgaard, H & Heitmann, M 2018, 'Kolesterolsænkende behandling med PCSK9-inhibitorer', Ugeskrift for Laeger, bind 180, nr. 20A, V11170831. <http://ugeskriftet.dk/videnskab/kolesterolsaenkende-behandling-med-pcsk9-inhibitorer>

APA

Røder, M. E., Hildebrandt, P., Storgaard, H., & Heitmann, M. (2018). Kolesterolsænkende behandling med PCSK9-inhibitorer. Ugeskrift for Laeger, 180(20A), [V11170831]. http://ugeskriftet.dk/videnskab/kolesterolsaenkende-behandling-med-pcsk9-inhibitorer

Vancouver

Røder ME, Hildebrandt P, Storgaard H, Heitmann M. Kolesterolsænkende behandling med PCSK9-inhibitorer. Ugeskrift for Laeger. 2018;180(20A). V11170831.

Author

Røder, Michael E ; Hildebrandt, Per ; Storgaard, Heidi ; Heitmann, Merete. / Kolesterolsænkende behandling med PCSK9-inhibitorer. I: Ugeskrift for Laeger. 2018 ; Bind 180, Nr. 20A.

Bibtex

@article{47326427c15c4e24a4fcfb3b5d93f28f,
title = "Kolesterols{\ae}nkende behandling med PCSK9-inhibitorer",
abstract = "Monoclonal antibodies inhibiting proprotein convertase subtilisin-kexin type 9 constitute a new class of lipid-lowering drugs. Currently, evolocumab and alirocumab are marketed. A recent cardiovascular outcome study with evolocumab has shown a cardiovascular (CV) event reduction of 15% in high-risk individuals at very low levels of low-density lipoproteins. The adverse event profile up to two years is mild. Treatment is very costly, and data on CV endpoints are still limited. Treatment is restricted to patients at very high risk of getting CV diseases and on a maximal tolerated statin and ezetimibe treatment in addition to dietary intervention.",
author = "R{\o}der, {Michael E} and Per Hildebrandt and Heidi Storgaard and Merete Heitmann",
year = "2018",
language = "Dansk",
volume = "180",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "20A",

}

RIS

TY - JOUR

T1 - Kolesterolsænkende behandling med PCSK9-inhibitorer

AU - Røder, Michael E

AU - Hildebrandt, Per

AU - Storgaard, Heidi

AU - Heitmann, Merete

PY - 2018

Y1 - 2018

N2 - Monoclonal antibodies inhibiting proprotein convertase subtilisin-kexin type 9 constitute a new class of lipid-lowering drugs. Currently, evolocumab and alirocumab are marketed. A recent cardiovascular outcome study with evolocumab has shown a cardiovascular (CV) event reduction of 15% in high-risk individuals at very low levels of low-density lipoproteins. The adverse event profile up to two years is mild. Treatment is very costly, and data on CV endpoints are still limited. Treatment is restricted to patients at very high risk of getting CV diseases and on a maximal tolerated statin and ezetimibe treatment in addition to dietary intervention.

AB - Monoclonal antibodies inhibiting proprotein convertase subtilisin-kexin type 9 constitute a new class of lipid-lowering drugs. Currently, evolocumab and alirocumab are marketed. A recent cardiovascular outcome study with evolocumab has shown a cardiovascular (CV) event reduction of 15% in high-risk individuals at very low levels of low-density lipoproteins. The adverse event profile up to two years is mild. Treatment is very costly, and data on CV endpoints are still limited. Treatment is restricted to patients at very high risk of getting CV diseases and on a maximal tolerated statin and ezetimibe treatment in addition to dietary intervention.

M3 - Tidsskriftartikel

C2 - 30274588

VL - 180

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 20A

M1 - V11170831

ER -

ID: 221828540